Send me real-time posts from this site at my email
Zacks

BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency

BioMarin Pharmaceutical Inc. BMRN announced that it will implement a restructuring initiative to save up to $50 million beginning next year. Management plans to use these savings by redirecting them toward the company’s operational activities.

This initiative is being taken up by BioMarin to efficiently allocate its cash resources and redirect them towards its R&D activities as well as support the upcoming commercial launches of its new drugs Roctavian (for hemophilia A) and Voxzogo (for achondroplasia) across multiple countries. Management also expects cost savings to improve the company’s operating margins.

To achieve these targets, BioMarin intends to reduce its workforce by nearly 4% or approximately 120 employees. The reduction is mainly expected from the company’s U.S. operations and a major portion of this workforce reduction is expected to be completed by this year’s end.

As a result of this workforce reduction, management expects to incur nearly $20-$25 million in pre-tax charges during this year in the third and fourth quarters as one-time cash expenses for severance and employee termination benefits. This restructuring intends to simplify BioMarin’s organizational structure and increase efficiency by minimizing the unnecessary management layers in the company’s chain of command.

Shares of BioMarin have risen 3.5% in the year-to-date period against the industry’s 25.3% decline.


Image Source: Zacks Investment Research

BioMarin is currently focused on introducing new gene therapy treatments in its portfolio. The newest drug in BioMarin’s portfolio is Roctavian (valoctocogene roxaparvovec, or valrox), gene therapy for severe hemophilia A, which received conditional marketing authorization in the European Union in August 2022.

Last month, management completed the refiling of the biologics license application (BLA) to the FDA, seeking approval for valrox gene therapy to treat adult patients with severe hemophilia A. BioMarin had previously submitted a BLA in 2019 for valrox to address hemophilia A. However, the FDA issued a complete response letter (CRL) to the BLA in 2020 citing dissatisfaction with the available data.

While resubmissions to the FDA are followed by a six-month review procedure, BioMarin also expects to submit additional data to strengthen its BLA filing. Based on these data submissions, management expects the review procedure to extend by three months.

If valrox is approved by the FDA, it will be the first gene therapy in the United States for hemophilia A. The gene therapy has been granted Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy and orphan drug designations by the FDA.

Another important candidate in the company’s pipeline is BMN 307, a gene therapy for phenylketonuria (PKU). In this regard, a phase I/II study on BMN 307 is currently ongoing.

 

Zacks Rank & Stocks to Consider

BioMarin currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Codiak BioSciences CDAK, Morphic MORF and Novartis NVS. While Morphic sports a Zacks Rank #1 (Strong Buy) at present, both Codiak BioSciences and Novartis carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for Morphic’s 2023 loss per share have narrowed $3.77 to $3.61 during the same period. Shares of Morphic have lost 35.9% in the year-to-date period.

Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.

In the past 60 days, estimates for Codiak BioSciences’ 2022 loss per share have narrowed from $1.94 to $1.81. During the same period, the loss estimates per share for 2023 have narrowed from $2.14 to $1.53. Shares of Codiak BioSciences have lost 93.3% in the year-to-date period.

Earnings of Codiak BioSciences beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 35.40%, on average. In the last reported quarter, CDAK delivered an earnings surprise of 61.54%.

In the past 60 days, estimates for Novartis’ 2022 earnings per share have increased from $6.06 to $6.07. Shares of Novartis have lost 13.1% in the year-to-date period.

Earnings of Novartis beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 1.39%, on average. In the last reported quarter, NVS delivered an earnings surprise of 3.31%.


This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation

Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.

>>Yes, I Want to Help Protect My Portfolio During the Recession

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novartis AG (NVS): Free Stock Analysis Report
 
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
 
Morphic Holding, Inc. (MORF): Free Stock Analysis Report
 
Codiak BioSciences, Inc. (CDAK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue